Drug Profile
Research programme: Chikungunya virus replication inhibitors - VenatoRx Pharmaceuticals
Latest Information Update: 28 Apr 2019
Price :
$50
*
At a glance
- Originator VenatoRx Pharmaceuticals
- Class
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chikungunya virus infections
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for research development in Chikungunya-virus-infections in USA (PO)